Free Trial

Aura Biosciences (AURA) Stock Forecast & Price Target

Aura Biosciences logo
$8.20 +0.09 (+1.11%)
(As of 12/20/2024 05:15 PM ET)

Aura Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
7

Based on 7 Wall Street analysts who have issued ratings for Aura Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 5 have given a buy rating, and 2 have given a strong buy rating for AURA.

Consensus Price Target

$23.00
180.49% Upside
According to the 7 analysts' twelve-month price targets for Aura Biosciences, the average price target is $23.00. The highest price target for AURA is $24.00, while the lowest price target for AURA is $22.00. The average price target represents a forecasted upside of 180.49% from the current price of $8.20.
Get the Latest News and Ratings for AURA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Aura Biosciences and its competitors.

Sign Up

AURA Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$23.00$23.00$21.67$21.00
Forecasted Upside180.49% Upside156.12% Upside126.40% Upside140.83% Upside
Consensus Rating
Buy
Buy
Buy
Buy

AURA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AURA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aura Biosciences Stock vs. The Competition

TypeAura BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.29
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside180.49% Upside25,828.59% Upside14.54% Upside
News Sentiment Rating
Very Positive News

See Recent AURA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024HC Wainwright
2 of 5 stars
E. White
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00+112.97%
10/18/2024Cowen
1 of 5 stars
 Reiterated RatingBuy ➝ Buy
10/18/2024Scotiabank
5 of 5 stars
George Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$20.00 ➝ $23.00+95.74%
10/18/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Julian Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$21.00 ➝ $24.00+113.33%
9/16/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/13/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $23.00+134.93%
9/9/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Dhankher
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:20 PM ET.


AURA Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Aura Biosciences is $23.00, with a high forecast of $24.00 and a low forecast of $22.00.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AURA shares.

According to analysts, Aura Biosciences's stock has a predicted upside of 180.49% based on their 12-month stock forecasts.

Aura Biosciences has been rated by research analysts at BTIG Research, Cowen, HC Wainwright, and Scotiabank in the past 90 days.

Analysts like Aura Biosciences more than other "medical" companies. The consensus rating for Aura Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AURA compares to other companies.


This page (NASDAQ:AURA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners